AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types (Q37851958)

From Wikidata

Jump to navigation Jump to search

scientific article published on March 2011

Language	Label	Description	Also known as
English	AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types	scientific article published on March 2011

Statements

scholarly article

1 reference

Europe PubMed Central

24 August 2017

1 reference

Europe PubMed Central

AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types (English)

1 reference

Europe PubMed Central

24 August 2017

cervix uterine cancer

1 reference

based on heuristic

inferred from title

1

object named as

Kate McKeage

1 reference

Europe PubMed Central

24 August 2017

author name string

Barbara Romanowski

2

1 reference

Europe PubMed Central

24 August 2017

publication date

1 March 2011

1 reference

Europe PubMed Central

24 August 2017

1 reference

Europe PubMed Central

24 August 2017

71

1 reference

Europe PubMed Central

24 August 2017

465-488

1 reference

Europe PubMed Central

24 August 2017

4

1 reference

Europe PubMed Central

24 August 2017

https://scigraph.springernature.com/pub.10.2165/11208090-000000000-00000

0 references

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice perspective

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Peroxisome proliterator-activated receptors, orphans with ligands and functions

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state.

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effect of fenofibrate on lipoprotein(a) in hypertriglyceridemic patients: impact of change in triglyceride level and liver function

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients.

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: a randomized, double-blind, placebo-controlled, multicenter, crossover study

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Efficacy and tolerability of a "suprabioavailable" formulation of fenofibrate in patients with dyslipidemia: a pooled analysis of two open-label trials

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidaemic hypertensive patients

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effects of fenofibrate on inflammatory cytokines and blood pressure in patients with hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effect of fenofibrate on the level of asymmetric dimethylarginine in individuals with hypertriglyceridemia.

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary mixed dyslipidemia.

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia.

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia.

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effect of fenofibrate on uric acid metabolism in Japanese hyperlipidemic patients.

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Fenofibrate raises plasma homocysteine levels in the fasted and fed states

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effects of fenofibrate and gemfibrozil on plasma homocysteine

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X.

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Fenofibrate inhibits angiogenesis in vitro and in vivo

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1β by suppressing AMP-activated protein kinase (AMPK) activation.

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects.

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: A 12-week, multicenter, randomized, open-label, parallel-group study

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Comparison of micronized fenofibrate and pravastatin in patients with primary hyperlipidemia

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effects of combination lipid therapy in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg.

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multic

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Normalization of metabolic syndrome using fenofibrate, metformin or their combination.

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study.

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Pharmacoepidemiology safety study of fibrate and statin concomitant therapy

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Reducing residual risk for patients on statin therapy: the potential role of combination therapy

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Advances in the medical treatment of diabetic retinopathy

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Preventing diabetic complications: a primary care perspective

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study.

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i).

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Safety considerations with fibrate therapy

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

CLA-1/SR-BI Is Expressed in Atherosclerotic Lesion Macrophages and Regulated by Activators of Peroxisome Proliferator-Activated Receptors

1 reference

https://api.crossref.org/works/10.2165%2F11208090-000000000-00000

21 January 2018

HPV & HPV vaccination: issues in developing countries.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of human papillomavirus vaccination and screening in Spain

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immune responses to human papillomavirus

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mathematical models of cervical cancer prevention in Latin America and the Caribbean

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and Immunogenicity of the HPV-16/18 AS04-Adjuvanted Vaccine: A Randomized, Controlled Trial in Adolescent Girls

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The epidemiology of human papillomavirus infections

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 2010

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Integrating clinical, community, and policy perspectives on human papillomavirus vaccination

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Measuring serum antibody to human papillomavirus following infection or vaccination.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost effectiveness of prophylactic HPV 16/18 vaccination in Finland: results from a modelling exercise.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double-blind, randomized, controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cervarix, the GSK HPV-16/HPV-18 AS04-adjuvanted cervical cancer vaccine, demonstrates stability upon long-term storage and under simulated cold chain break conditions.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human papillomavirus and cervical cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The cervical cancer epidemic that screening has prevented in the UK.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix™, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Psychological costs of inadequate cervical smear test results.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Health Technology Assessment of bivalent HPV vaccine Cervarix in Italy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of Innate Immune Factors in the Adjuvant Activity of Monophosphoryl Lipid A

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix].

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21395359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11208090-000000000-00000

1 reference

Europe PubMed Central

24 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

24 August 2017

reason for deprecated rank

incorrect identifier value

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37851958&oldid=2130245453"